LBY 135

Drug Profile

LBY 135

Alternative Names: LBY135

Latest Information Update: 11 Aug 2011

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Jun 2008 Adverse events, efficacy, PK and IG data from a phase I trial in advanced solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 28 Apr 2008 Phase-I clinical trials in Cancer in USA (Parenteral)
  • 08 May 2007 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top